Company intelligence / Profile preview

Izana Bioscience

London, England, United Kingdom

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Namilumab, a human monoclonal antibody targeting GM-CSF, has shown efficacy in a phase II proof-of-concept trial in over 100 rheumatoid arthritis patients and was well tolerated. The company has received Innovate UK funding to support further phase II studies in ankylosing spondylitis. Preclinical work continues on orally delivered mitochondrial protective agents for rare diseases

Therapeutic areas: Rare DiseasesRheumatologyImmunology
Modalities: Monoclonal antibodies (notably namilumab)Mitochondrial protective therapeutics (preclinical)
Industry: Biotech

Partnerships

Takeda Pharmaceutical Company – exclusive worldwide license agreement for namilumab development/manufacture/commercialization and strategic equity stake.

Beyond the preview

Go deeper on Izana Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Izana Bioscience.